abbvie glp-1 receptor agonist medications Agonists as Treatments for Type 2 Diabetes abbvie glp-1 receptor agonists weight

The novel peptide is biased towards GLP-1R agonism versus GCGR with a 3-4 fold reduced potency at the GLP-1R compared to native GLP-1 and around an 8-fold reduced potency at the GCGR compared to native glucagon

In April 2025, the Trump administration reversed a Biden-era decision and announced that Medicare would no longer cover GLP-1 medications specifically for weight loss

While superior to placebo, this falls slightly below the commonly cited 5 % threshold considered clinically meaningful for individuals with a BMI below 35 kg/m, and well below the larger reductions often recommended for those with severe obesity

Overall, semaglutide demonstrated substantially greater weight-loss efficacy than earlier GLP-1 receptor agonists in adolescent populations

Diabetes Care 48 , 846859 (2025)

Jepsen MM, Christensen MB (2021) Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity